Sale

Haemophilia Treatment Market

Global Haemophilia Treatment Market Share, Size, Growth, Analysis, Forecast: By Disease Type: Haemophilia A, Haemophilia B, Hemophilia C, Others; By Product Type: Recombinant Coagulation Factor Concentrates, Others; By Therapy Type; By Treatment Channel; By Distribution Channel; Regional Analysis; Competitive Landscape; 2024-2032

Global Haemophilia Treatment Market Outlook

The global haemophilia treatment market size reached a value of about USD 14.84 billion in 2023. The market is expected to grow at a CAGR of 7.5% during the forecast period of 2024-2032 to attain a value of USD 28.44 billion by 2032, driven by the rising prevalence of increased rapid advancement in the industry and increasing awareness among people.

 

Global Haemophilia Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Haemophilia Treatment Market: Introduction and Overview

Haemophilia is a condition in which the blood clotting does not take place in the human body. The amount of blood clotting depends on the level of severity of the condition in the patient. Haemophilia happens when a human body lacks of blood clotting proteins hence, unable to clot the blood. Symptoms of haemophilia include bleeding in different parts of the body which may occur occasionally and spontaneously.

 

The market is growing rapidly and is expected to continue growing in the coming years as well. The major role is played by the governments and organizations that are continuously putting efforts in spreading awareness about haemophilia treatment globally. Also, the increased rate of research and development to determine the appropriate and effective treatments and therapies for the condition is among the major factors that are aiding the rapid growth of the global haemophilia market.

 

North America has been the leading region in the industry and contributed to a significant market share. It is expected to be doing the same for the forecast period as well. The reason behind North America being the leader of the treatment market is the rapid advancing of the technologies that are used to develop advanced products for the patients. The increasing prevalence of haemophilia is also a major reason for the rise of the global haemophilia treatment market share in North America.

 

Market Segmentations:

The haemophilia treatment market can be segmented into different categories such as disease type, product type, therapy type, treatment channel, distribution channel, and region.

 

Global Haemophilia Treatment Market By Product Type

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Diseases Type

  • Haemophilia A
  • Haemophilia B
  • Haemophilia C
  • Others

 

Market Breakup by Product Type

  • Recombinant Coagulation Factor Concentrate
  • Plasma Derived Coagulation Factor Concentrate
  • Desmopressin
  • Antifibrinolytics Agents

 

Market Breakup by Therapy Type

  • Replacement Therapy
  • Immune Tolerance Induction Therapy
  • Others

 

Market Breakup by Treatment Channel

  • Public
  • Private

 

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

 

Global Haemophilia Treatment Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

Global Haemophilia Treatment Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Haemophilia Treatment Market: Treatment Ladscape

There are significant research and developments going on in the market. Some of them have not been approved yet and some of them are in use already. However, the market is continuously developing and growing. The most recent key developments that have been introduced in the market to cure the haemophilia include the use of concentrates of plasma derived factors in the treatment. Liquid component of the blood is called plasma. It is commonly pale-yellow in colour and contains proteins like albumin, clotting factors, and antibodies. These plasma proteins are used in the composition of various factor concentrate therapeutic solutions. The human blood has to undergo several processes to split into different components such as clotting factors.

 

Other key drugs used in the treatment market are as follows:

  • HEMLIBRA

Instead of directly replacing the lost clotting factor VIII, HEMLIBRA functions to replace factor VIII functions. It can be applied to haemophilia A patients to either stop or lessen the frequency of bleeding episodes. This can be administered by skin injections.

 

  • DDAVP

The drug DDAVP and Stimate resemble a hormone that the body naturally produces. Factor VIII is kept in the bodily tissues and is released by the drugs. This can help people with mild and moderate haemophilia by self-increasing the level of factor VIII.

 

  • Amicar

This is a drug that could be taken directly via mouth or in veins through injections. It could be in the form of a pill or a liquid. This drug helps in developing a stronger blood clot that does not break down easily.

 

Competitive landscape:

This report gives a detailed analysis of the following key players in the global haemophilia treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds. The key players in the market are as follows:

 

  • Novo Nordisk A/S
  • Pfizer Inc
  • Bayer AG
  • Biogen Inc.
  • CSL Behring
  • Grifols SA
  • Octapharma AG
  • Kedrion S.p.A Ferring Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Diseases Type
  • Product Type
  • Therapy Type
  • Treatment Channel
  • Distribution Channel
  • Region
Breakup by Diseases Type
  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Others
Breakup by Product Type
  • Recombinant Coagulation Factor Concentrates
  • Plasma Derived Coagulation Factor Concentrate
  • Desmopressin
  • Antifibrinolytics Agents
Breakup by Therapy Type
  • Replacement Therapy
  • Gene Therapy
  • Immune Tolerance Induction Therapy
  • Others
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Bayer AG
  • Biogen Inc.
  • CSL Behring
  • Grifols SA
  • Octapharma AG
  • Kedrion S.p.A.
  • Ferring Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.

 

Haemophilia Treatment Market Report Snapshots

Haemophilia Treatment Market Size

Haemophilia Treatment Companies

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Haemophilia Diseases Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Haemophilia Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Haemophilia Epidemiology (2016-2031)
    5.3    Europe Haemophilia Epidemiology (2016-2031)
    5.4    Asia Pacific Haemophilia Epidemiology (2016-2031)
    5.5    Latin America Haemophilia Epidemiology (2016-2031)
    5.6    Middle East and Africa Haemophilia Epidemiology (2016-2031)
6    Global Haemophilia Treatment Market Overview
    6.1    Global Haemophilia Treatment Market Historical Value (2017-2023) 
    6.2    Global Haemophilia Treatment Market Forecast Value (2024-2032)
7    Global Haemophilia Treatment Market Landscape
    7.1     Haemophilia Treatment Product Landscape
        7.1.1    Analysis by Diseases Type
        7.1.2    Analysis by Product Type
        7.1.3    Analysis by Therapy Type
        7.1.4    Analysis by Treatment Channel
        7.1.5    Analysis by Distribution Channel
        7.1.6    Analysis by Region
    7.2    Haemophilia Treatment: Developers Landscape
        7.2.1    Analysis by Year of Establishment
        7.2.2    Analysis by Company Size
        7.2.3    Analysis by Region
8    Haemophilia Treatment Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Haemophilia Treatment Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Haemophilia Treatment Market Segmentation
    11.1    Global Haemophilia Treatment Market by Diseases Type
        11.1.1    Market Overview
        11.1.2    Hemophilia A
        11.1.3    Hemophilia B
        11.1.4    Hemophilia C
        11.1.5    Others
    11.2    Global Haemophilia Treatment Market by Product Type
        11.2.1    Market Overview
        11.2.2    Recombinant Coagulation Factor Concentrates
        11.2.3    Plasma Derived Coagulation Factor Concentrate
        11.2.4    Desmopressin
        11.2.5    Antifibrinolytics Agents
    11.3    Global Haemophilia Treatment Market by Therapy Type
        11.3.1    Market Overview
        11.3.2    Replacement Therapy
        11.3.3    Gene Therapy
        11.3.4    Immune Tolerance Induction Therapy
        11.3.5    Others
    11.4    Global Haemophilia Treatment Market by Treatment Channel
        11.4.1    Market Overview
        11.4.2    Public
        11.4.3    Private
    11.5    Global Haemophilia Treatment Market by Distribution Channel
        11.5.1    Market Overview
        11.5.2    Hospital Pharmacy
        11.5.3    Retail Pharmacy
        11.5.4    Online Pharmacy
        11.5.5    Others
    11.6    Global Haemophilia Treatment Market by Region
        11.6.1    Market Overview
        11.6.2    North America
        11.6.3    Europe 
        11.6.4    Asia Pacific
        11.6.5    Latin America
        11.6.6    Middle East and Africa
12    North America Haemophilia Treatment Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Haemophilia Treatment Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Haemophilia Treatment Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Haemophilia Treatment Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Haemophilia Treatment Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Novo Nordisk A/S
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Pfizer Inc.
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Bayer AG
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Biogen Inc.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    CSL Behring
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Grifols SA
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Octapharma AG
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Kedrion S.p.A.
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Ferring Pharmaceuticals Inc.
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    F. Hoffmann-La Roche Ltd.
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
24    Haemophilia Treatment Market- Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of USD 14.84 billion in 2023.

The market is likely to grow at a CAGR of 7.5% during the forecast period of 2024-2032 to attain a value of USD 28.44 billion by 2032.

The different types include Haemophilia A, B, and C, among others.

The product types include recombinant coagulation factor concentrate, plasma derived coagulation factor, concentrate, desmopressin, and antifibrinolytics agents.

The therapies can be categorised into replacement therapy, gene therapy, and immune tolerance induction therapy, among others.

The treatment channels include private and public channels.

The distribution channels include hospital pharmacy, retail pharmacy, and online pharmacy, among others.

Key players of the market are Novo Nordisk A/S, Pfizer Inc, Bayer AG, Biogen Inc., CSL Behring, Grifols SA, Octapharma AG, Kedrion S.p.A Ferring Pharmaceuticals Inc., and F. Hoffmann-La Roche Ltd.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER